Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Di Lorenzo

Showing results (1-10 of 349) with videos related to

Pageof 35
Sort By:
European Urology|May 1, 2020
Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol 2020;78:e2-3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?Giuseppe Di Lorenzo
European Urology|June 19, 2007
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10Giuseppe Di Lorenzo
European Urology|April 21, 2007
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceGiuseppe Di Lorenzo
The Lancet. Oncology|November 3, 2007
Estramustine in prostate cancer: new look at an old drugGiuseppe Di Lorenzo
European Urology|January 4, 2011
A prognostic model for patients with metastatic renal cell cancer: what's new?Giuseppe Di Lorenzo
Critical Reviews in Oncology/Hematology|July 29, 2008
Update on classic Kaposi sarcoma therapy: new look at an old diseaseGiuseppe Di Lorenzo
Nature Reviews. Urology|July 10, 2010
Kidney cancer: overall survival is an unsuitable primary end pointGiuseppe Di Lorenzo, Carlo Buonerba
European Urology|April 2, 2013
Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapyGiuseppe Di Lorenzo, Carlo Buonerba
Nature Reviews. Urology|June 11, 2010
An evolving role for immunotherapy in metastatic RCCRiccardo Autorino, Giuseppe Di Lorenzo
Future Oncology (London, England)|September 5, 2015
The expanding role of chemotherapy in prostate cancerGiuseppe Di Lorenzo, Guru Sonpavde
Pageof 35

Showing results (1-10 of 349) with videos related to

Sort By:
Pageof 35
European Urology|May 1, 2020
Re: Silke Gillessen Sommer, Thomas Powles. Advice for Medical Oncology Care of Urological Cancer Patients During the COVID-19 Pandemic. Eur Urol 2020;78:e2-3: Is It Always Correct to Continue Androgen Receptor Signaling Inhibitors in the COVID-19 Era?Giuseppe Di Lorenzo
European Urology|June 19, 2007
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10Giuseppe Di Lorenzo
European Urology|April 21, 2007
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experienceGiuseppe Di Lorenzo
The Lancet. Oncology|November 3, 2007
Estramustine in prostate cancer: new look at an old drugGiuseppe Di Lorenzo
European Urology|January 4, 2011
A prognostic model for patients with metastatic renal cell cancer: what's new?Giuseppe Di Lorenzo
Critical Reviews in Oncology/Hematology|July 29, 2008
Update on classic Kaposi sarcoma therapy: new look at an old diseaseGiuseppe Di Lorenzo
Nature Reviews. Urology|July 10, 2010
Kidney cancer: overall survival is an unsuitable primary end pointGiuseppe Di Lorenzo, Carlo Buonerba
European Urology|April 2, 2013
Words of wisdom: Re: Abiraterone in metastatic prostate cancer without previous chemotherapyGiuseppe Di Lorenzo, Carlo Buonerba
Nature Reviews. Urology|June 11, 2010
An evolving role for immunotherapy in metastatic RCCRiccardo Autorino, Giuseppe Di Lorenzo
Future Oncology (London, England)|September 5, 2015
The expanding role of chemotherapy in prostate cancerGiuseppe Di Lorenzo, Guru Sonpavde
Pageof 35